The pathogenic activation of CS in human SLE was early described [33,34], including low total hemolytic activity of complement (CH50) and decreased levels of C3 and C4, particularly in patients with most severe manifestations such as active nephritis [35]. Here, C4A is linked to systemic lupus erythematosus.